SYMPOSIUM: OPEN QUESTIONS ON MIGRAINE

Neurological Sciences

, Volume 33, Issue 1, pp 65-69

Open Access This content is freely available online to anyone, anywhere at any time.

Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies

  • Gianni AllaisAffiliated withDepartment of Gynecology and Obstetrics, Women’s Headache Center, University of Turin Email author 
  • , Vincenzo TulloAffiliated withDepartment of Clinical Neurosciences, Carlo Besta National Neurological Institute
  • , Stefano OmboniAffiliated withItalian Institute of Telemedicine
  • , Chiara BenedettoAffiliated withDepartment of Gynecology and Obstetrics, Women’s Headache Center, University of Turin
  • , Grazia SancesAffiliated withHeadache Centre, IRCCS C. Mondino Foundation, Institute of Neurology
  • , Dario ZavaAffiliated withIstituto Lusofarmaco d’Italia
  • , Michel D. FerrariAffiliated withDepartment of Neurology, Leiden Centre for Translational Neuroscience, Leiden University Medical Centre
  • , Gennaro BussoneAffiliated withDepartment of Clinical Neurosciences, Carlo Besta National Neurological Institute

Abstract

The objective of this study was to review the efficacy and safety of frovatriptan (F) versus rizatriptan (R), zolmitriptan (Z) and almotriptan (A), in women with menstrually related migraine (IHS criteria) through a pooled analysis of three individual studies. Subjects with a history of migraine with or without aura were randomized to F 2.5 mg or R 10 mg (study 1), F or Z 2.5 mg (study 2), and F or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double-blind, crossover design. After treating three episodes of migraine in no more than 3 months with the first treatment, patients had to switch to the next treatment for other 3 months. 346 subjects formed intention-to-treat population of the main study; 280 of them were of a female gender, 256 had regular menses and 187 were included in the menstrual migraine subgroup analysis. Rate of pain free at 2, 4 and 24 h was 23, 52 and 67 % with F and 30, 61 and 66 % with comparators (P = NS). Pain relief episodes at 2, 4 and 24 h were 37, 60 and 66 % for F and 43, 55 and 61 % for comparators (P = NS). Rate of recurrence was significantly (P < 0.05) lower under F either at 24 h (11 vs. 24 % comparators) or at 48 h (15 vs. 26 % comparators). Number of menstrual migraine attacks associated with drug-related adverse events was equally low (P = NS) between F (5 %) and comparators (4 %).

Keywords

Almotriptan Menstrually related migraine Frovatriptan Rizatriptan Zolmitriptan